Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9% - Time to Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report)'s share price fell 3.9% during mid-day trading on Thursday . The company traded as low as $14.27 and last traded at $14.07. 81,809 shares traded hands during trading, a decline of 90% from the average session volume of 841,059 shares. The stock had previously closed at $14.64.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on KROS. Scotiabank reduced their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. HC Wainwright reduced their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wedbush reiterated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday. Truist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Finally, Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Keros Therapeutics Stock Performance

The business's fifty day moving average is $13.00 and its 200-day moving average is $19.73. The firm has a market cap of $579.58 million, a P/E ratio of -2.74 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter last year, the business earned ($1.21) EPS. Analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 20.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KROS. Barclays PLC raised its holdings in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. SG Americas Securities LLC bought a new position in Keros Therapeutics during the 4th quarter worth approximately $388,000. Exchange Traded Concepts LLC bought a new position in Keros Therapeutics during the 4th quarter worth approximately $99,000. China Universal Asset Management Co. Ltd. raised its holdings in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after purchasing an additional 1,372 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.